Phenylacetamides suitable as protein kinase inhibitors

Details for Australian Patent Application No. 2006233688 (hide)

Owner Novartis AG

Inventors Bold, Guido; Furet, Pascal; Vaupel, Andrea; Mccarthy, Clive; Guagnano, Vito

Agent Davies Collison Cave

Pub. Number AU-A-2006233688

PCT Pub. Number WO2006/108640

Priority 0507575.9 14.04.05 GB

Filing date 12 April 2006

Wipo publication date 19 October 2006

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/4184 (2006.01)

A61K 31/4188 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

C07D 235/04 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings

Event Publications

25 October 2007 PCT application entered the National Phase

  PCT publication WO2006/108640 Priority application(s): WO2006/108640

6 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006233691-Organic compounds

2006233675-Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues